Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.74 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.74 |
| ▸ | MGLL | Q99685 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8024709 | 0.87 | BCL9 (0.64) | BCL9CTNNB1MGLLGAAMAPT | |
| SCHEMBL27678357 | 0.86 | BCL9 (0.68) | BCL9CTNNB1MGLLGAAMAPT | |
| SCHEMBL133257 | 0.85 | BCL9 (1.00) | BCL9CTNNB1MGLLGAAMAPT | |
| SCHEMBL26111924 | 0.84 | BCL9 (0.97) | BCL9CTNNB1MGLLGAAMAPT | |
| SCHEMBL7063519 | 0.82 | GAA (0.65) | BCL9CTNNB1MGLLGAAMAPT | |
| SCHEMBL28018668 | 0.81 | BCL9 (0.57) | BCL9CTNNB1MGLLGAAMAPT | |
| SCHEMBL8211918 | 0.80 | BCL9 (0.52) | BCL9CTNNB1MGLLGAAMAPT | |
| Butyric Acid SCHEMBL2307779 | 0.80 | BCL9 (0.88) | BCL9CTNNB1MGLLGAAMAPT | |
| SCHEMBL9403286 | 0.80 | LMNA (0.52) | BCL9CTNNB1GAAMAPTKMT2A | |
| SCHEMBL3989423 | 0.80 | GAA (0.62) | BCL9CTNNB1MGLLGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188267-B1 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | GILEAD CONNECTICUT INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-9249123-B2 | Pyridinones/pyrazinones, method of making, and method of use thereof | GENENTECH, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2611790-B1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20130281432-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| EP-2611790-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8247550-B2 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| WO-2012031004-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20110059944-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7884108-B2 | tyrosine kinase inhibitors such as N-(3-(6-(4-(1,4-Dimethyl-3-oxopiperazin-2-yl)phenyl amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-fluorophenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide for treating bone disorders, allergic disorders, autoimmune diseases, inflammatory diseases | CGI PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-2188267-A2 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | CGI Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009039397-A2 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | CGI PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059944-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | BCL9 31/4885CTNNB1 4861/4885MGLL 345/4885 |
| US-20130281432-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, PDXK, TYK2 | BCL9 1358/4885CTNNB1 2998/4885MGLL 4645/4885 |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | BCL9 31/4885CTNNB1 4861/4885MGLL 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.